Biogen is exercising its option to acquire an acute ischemic stroke candidate from TMS after getting a look at phase 2a data. The results persuaded Biogen to pay $18 million for a small molecule that may expand the time window in which thrombolytics can safely be used to clear clots.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,